cancer chemotherapy drugs to be used, based on in vitro analysis of their effects on cancer cells taken from an individual.

(E) Topical application of oxygen.
(F) Immunotherapy for malignant disease.
(G) Prolotherapy, joint sclerotherapy, and ligamentous injections with sclerosing agents.
(H) Transcervical block silicone plug.
(I) Whole body hyperthermia in the treatment of cancer.
(J) Portable nocturnal hypoglycemia detectors.
(K) Testosterone pellet implants in the treatment of females.
(L) Estradiol pellet implants.
(M) Epikeratophakia for treatment of aphasial and myopia.
(N) Bladder stimulators.
(O) Ligament replacement with absorbable copolymer carbon fiber scaffold.
(P) Intraoperative radiation therapy.
(Q) Gastric bubble or balloon.
(R) Single and dual photon absorptiometry for the detection and monitoring of osteoporosis.
(S) Dorsal root entry zone (DREZ) thermocoagulation or microcoagulation neurosurgical procedure.
(T) Brain electrical activity mapping (BEAM).
(U) Topographic brain mapping (TBM) procedure.
(V) Ambulatory blood pressure monitoring.
(W) Bilateral carotid body resection to relieve pulmonary symptoms.
(X) Intracavitary administration of cisplatin for malignant disease.
(Y) Cervicography.
(Z) Ambulatory home monitoring—uterine contractions.
(AA) Sperm evaluation, hamster penetration test.
(BB) Transfer factor (TF).
(CC) Continuous ambulatory esophageal pH monitoring (CAEpHM) is considered investigational for patients under age 12 for all indications, and for patients over age 12 for sleep apnea.
(DD) Adrenal-to-brain transplantation for Parkinson’s disease.
(EE) Videofluoroscopic evaluation in speech pathology.
(FF) Herniography.
(GG) Applied kinesiology.
(HH) Hair analysis to identify mineral deficiencies from the chemical composition of the hair. Hair analysis testing may be reimbursed when necessary to determine lead poisoning.
(I) Iniology (links flaws in eye coloration with diseases elsewhere in the body).
(JJ) Small intestinal bypass (jejunal ileal bypass) for treatment of morbid obesity.
(KK) Biliopancreatic bypass.
(LL) Gastric wrapping/gastric banding.
(MM) Calcium EAP/calcium orotate and selenium (also known as Nieper therapy)—Involves inpatient care and use of calcium compounds and other non-FDA approved drugs and special diets. Used for cancer, heart disease, diabetes, and multiple sclerosis.
(NN) Percutaneous balloon valvuloplasty for mitral and tricuspid valve stenosis.
(OO) Amniocentesis performed for fetal deposition to the ABO blood antigens.
(PP) Balloon dilatation of the prostate.
(QQ) Helium in radiosurgery.
(RR) Palladium 103 seed brachytherapy.
(SS) Electrostimulation of salivary production in the treatment of xerostomia secondary to Sjorgren’s syndrome.
(TT) Interoperative monitoring of sensory evoked potentials (SEP). To include visually evoked potentials, brainstem auditory evoked response, somatosensory evoked potentials during spinal and orthopedic surgery, and sensory evoked potentials monitoring of the sciatic nerve during total hip replacement. Recording SEPs in unconscious head injured patients to assess the status of the somatosensory system. The use of SEPs to define concomital or gestational age in preterm infants.
(UU) Autolymphocyte therapy (ALT) (immunotherapy used for treating metastatic kidney cancer patients).
(VV) Radiation immunoguided surgery in the detection of cancer.
(WW) HLA-DNA typing.
(XX) Gait analysis (also known as a walk study or electrodynogram).
(YY) Cryosurgery for liver metastases.
(ZZ) Use of cerebellar stimulators/pacemakers for the treatment of neurologic disorders.
(AAAA) Signal-averaged ECG.
(BBB) Intraventricular administration of narcotics.
(CCCC) Peri-urethral Teflon injections to manage urinary incontinence.
-DDD) Extraoperative electrocorticography for stimulation and recording in order to determine electrical thresholds of neurons as an indicator of seizure focus.
-EEE) Quantitative computed tomography (QCT) for the detection and monitoring of osteoporosis.
-FFF) Percutaneous transluminal angioplasty in the treatment of obstructive lesions of the carotid, vertebral or cerebral arteries.
-GGG) Endoscopic third ventriculostomy.
(HHH) Holding therapy—Involves holding the patient in an attempt to achieve interpersonal contact, and to improve the patient’s ability to concentrate on learning tasks.
(I) In terato fetal surgery.
(jj) Light therapy for seasonal depression (also known as seasonal affective disorder (SAD)).
(KKK) Transurethral laser incision of the prostate (TULIP).
(LLL) Contigen Bard® collagen implant.
(MMM) Dorsal column and deep brain electrical stimulation of treatment of motor function disorder.
(NNN) Chelation therapy, except under specific conditions.
(OOO) All organ transplants except heart, heart-lung, lung, kidney, some bone marrow, liver, liver-kidney, corneal, and heart-valve.
(PPP) Implantable infusion pumps, except for hepatic artery perfusion chemotherapy for the treatment of primary liver cancer or metastatic colorectal liver cancer.
(QQQ) Services related to the candidiasis hypersensitivity syndrome, yeast syndrome, or gastrointestinal candidiasis (i.e., allergenic extracts of Candida albicans for immunotherapy and/or provocation/neutralization).
(RRR) Treatment of chronic fatigue syndrome.
(SSS) Extracorporeal immunoadsorption using protein A columns for conditions other than acute idiopathic thrombocytopenia purpura.
(TTT) Dynamic posturography (both static and computerized).
(UUU) Laparoscopic myomectomy.
(VVV) Growth factor, including platelet-derived growth factors, for treating non-healing wounds. This includes procuremen®, a platelet-derived wound-healing formula.
(WWW) High dose chemotherapy with stem cell rescue (HDC/SCR) for any of the following malignancies:

1. Breast cancer.
2. Ovarian cancer.
3. Testicular cancer.
4. Multiple myeloma.

* * * * *

L.M. Bynum,
Alternate OSD Federal Register Liaison Officer, Department of Defense.
[FR Doc. 95-12031 Filed 5-17-95; 8:45 am]
BILLING CODE 5000-04-M
DEPARTMENT OF TRANSPORTATION

Coast Guard

33 CFR Part 117

[CGD09–95–004]

Drawbridge Operation Regulations; Chicago River, IL

AGENCY: Coast Guard, DOT.

ACTION: Notice of establishment of negotiated rulemaking committee and first meeting.

SUMMARY: The Coast Guard establishes a negotiated rulemaking committee to develop regulations governing the operation of Chicago owned drawbridges over the Chicago River in Chicago, Illinois and the passage of recreational vessels under those bridges. The committee is established in accordance with the Negotiated Rulemaking Act of 1990 and the Federal Advisory Committee Act.

DATES: The first meeting of the negotiated rulemaking committee will be held on June 5, 1995 between 9:00 A.M. and 5:00 P.M. Additional meetings will be held on June 14, 1995, June 20, 1995, June 28, 1995 and July 12, 1995, at the same times and place, unless otherwise scheduled by the committee.

ADDRESSES: The committee meetings will be held in room 326, Ralph H. Metcalf Federal Building, 77 West Jackson Street, Chicago, Illinois, 60604.

FOR FURTHER INFORMATION CONTACT: Carolyn Malone, Ninth District Bridge Branch, Ninth Coast Guard District, 1240 East Ninth Street, room 2083, Cleveland, Ohio, (216) 522–3993 between the hours of 8:00 A.M. and 3:00 P.M. Should the dates, times or location of any subsequent committee meeting change, recorded information will be provided at the above telephone number outside of those hours.

SUPPLEMENTARY INFORMATION: The Coast Guard published a notice of intent (notice) to form a negotiated rulemaking committee on April 10, 1995 (60 FR 18061). The notice discussed the Coast Guard’s intention to proceed in accordance with the Negotiated Rulemaking Act of 1990 (Pub. L. 101–648) and establish the Chicago Drawbridge Negotiated Rulemaking Committee (committee) to develop regulations that provide a permanent and acceptable resolution to the issues involved in drawbridge openings for recreational vessels on the Chicago River. Regulations governing the operation of the drawbridges are located at 33 CFR 117.391 and are issued under the authority of 33 U.S.C. 499. The notice also identified interests that would be affected by amendments to the current regulations. The Coast Guard solicited comments on the issues raised in the notice and nominations for membership on the committee. The closing date for comments and nominations was May 8, 1995.

No comments were received on the issues to be considered by the committee. Several nominations for membership were received. Separate discussions were held by the neutral facilitator engaged by the Coast Guard with each of the interests identified in the notice and with others identified during the comment period. As a result, the Coast Guard is establishing the committee and beginning the negotiation process. As required by the Federal Advisory Committee Act (5 U.S.C. App.) (FACA), the committee charter has been approved by the Secretary of Transportation and submitted to the General Services Administration. The following interests are represented on the committee: the City of Chicago, boarder owners, boaters, commercial interests in Chicago, and the Coast Guard.

The first meeting of the committee will be held in Chicago on June 5, 1995 at the time and location indicated at the beginning of this notice. The purpose of the first meeting is to: (1) Discuss the charter, goals, and mission of the committee; (2) present the issues to be considered by the committee; and (3) approve the organizational protocols by which the committee will operate. At the first session, there will be discussion of the negotiation and rulemaking process and an explanation of the statutory basis for the Coast Guard’s drawbridge regulations.

The schedule of additional meetings provided earlier in this notice will be considered by the committee at its first meeting. In order for new regulations to be effective for the Fall 1995 close of the boating season, committee meetings must be concluded by July 12, 1995. Therefore, this schedule may be changed and additional meetings may be held on short notice. Announcements of these meetings will be published in the Federal Register if time for meaningful advance notice is available. Information on all meetings of the committee will be available by calling (216) 522–3993 or from the contact person indicated at the beginning of this notice.

Attendance at committee meetings is open to the public, subject to space availability. Persons wishing to present oral statements at the meeting should notify the contact person no later than the day before the meeting. Any member of the public may submit written statements to the committee at any time, also through the contact person.


Paul J. Pluta,

Captain, United States Coast Guard,

Commander, Ninth Coast Guard District, Acting.

[FR Doc. 95–12284 Filed 5–17–95; 8:45 am]
BILLING CODE 4910–14–M

ENVIRONMENTAL PROTECTION AGENCY

40 CFR Part 51

[FRL–5208–2]

Inspection and Maintenance Flexibility Amendments

AGENCY: Environmental Protection Agency.

ACTION: Proposed rule; extension of public comment period.

SUMMARY: This action extends the comment period to the proposed rule published on April 28, 1995 (60 FR 20934). EPA is extending the comment period to June 1, 1995.

DATES: Written comments on the proposed rule must be received no later than June 1, 1995. A public hearing is scheduled for May 17, 1995 and will be held at Weber’s Inn at 3050 Jackson Road, Ann Arbor, Michigan 48103, from 9 a.m. through 5 p.m.

ADDRESSES: Interested parties may submit written comments (in duplicate if possible) to Public Docket No. A–95–08. It is requested that a duplicate copy be submitted to Eugene J. Tierney at the Office of Mobile Sources, National Vehicle and Fuel Emissions Laboratory, 2565 Plymouth Road, Ann Arbor, Michigan, 48105. The docket is located at the Air Docket, Room M–1500 (6102), Waterside Mall SW., Washington, DC 20460. The docket may be inspected between 8:30 a.m. and 12 noon and between 1:30 p.m. until 3:30 p.m. on weekdays. A reasonable fee may be charged for copying docket material.

FOR FURTHER INFORMATION CONTACT: Eugene J. Tierney, Telephone (313) 668–4456.

SUPPLEMENTARY INFORMATION:

Background

EPA announced its intent to amend the I/M Program Requirements in December 1994 and held stakeholders’ meetings on January 24, 1995 and January 31, 1995. The proposal creates a second, less stringent enhanced I/M performance standard that could be